Opus Genetics, Inc.

NASDAQ:IRD

Biotechnology

Healthcare
$3.92 -0.12%

-$0.01 today

Market cap
$326.13M
Beta
0.55
P/E (TTM)
-33.0
EPS (TTM)
-$0.12
52W Low $0.90High $5.81

Volume 0.75M

Average 0.81M

IRD Other Non-current Liabilities

Long-term obligations not reported separately, such as lease or pension liabilities.

Opus Genetics, Inc.NASDAQ: IRD

Other Non-current Liabilities · Q1 FY2026 · quarter ended Mar 2026

Other non-current liabilities rises 310.5% from a year ago

Other non-current liabilities stood at $77.35M at the end of Q1 FY2026, up 310.5% from a year earlier and up 185.3% from the prior quarter.

Context

  • Other non-current liabilities amounted to 115.8% of total assets at the end of Q1 FY2026, up 76.7 pp from a year earlier.
  • Other non-current liabilities increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether other non-current liabilities keeps rising in the next quarterly balance sheet after a +310.5% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$77.35M+185.3% QoQ
Last fiscal yearDec 2025
$27.11M+43.9% YoY
Year agoMar 2025
$18.84M+310.5% since
Other Non-current Liabilities past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+310.5%——
1 year+43.9%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Other Non-current Liabilities history

USD · from the balance sheet

Latest · FY2025
27.11M USD
Year-over-year change
+43.9%

Other Non-current Liabilities vs competitors

How IRD compares with its peers on the latest reported figures

  • IRD's Mar 2026 other non-current liabilities of $77.35M is the highest of the 10 companies compared; the peer median is $8K.
  • Its year-over-year change of +310.5% is the highest of 7, against a peer median of -57.7%.
  • Other non-current liabilities amounts to 115.8% of total assets for IRD, versus a peer median of 0.0%.
IRD Competitors Peer median
Other Non-current Liabilities for IRD and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
IRDOpus Genetics, Inc.Mar 2026$77.35M +310.5%—115.8%
MCRBSeres Therapeutics, Inc.Mar 2026$2.14M +13.0%+12.9%1.8%
ALECAlector, Inc.Mar 2026$1.77M +27.0%+31.8%0.7%
AGENAgenus Inc.Mar 2026$247K -99.9%-89.4%0.1%
SEERSeer, Inc.Mar 2026$26K -16.1%-70.8%0.0%
TILInstil Bio, Inc.Mar 2026$8K -99.2%-90.1%0.0%
INOInovio Pharmaceuticals, Inc.Mar 2026$0 ——0.0%
CGTXCognition Therapeutics, Inc.Mar 2026$0 ——0.0%
ABOSAcumen Pharmaceuticals, Inc.Mar 2026$0 -100.0%—0.0%
HURATuHURA Biosciences, Inc.Mar 2026-$1 ——0.0%
Peer median (excluding IRD) $8K-57.7%-70.8%0.0%

Competitors are the stored peer set for IRD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents24.53M42.63M50.5M30.32M45.09M
Short-term Investments219K49K15K2K0
Net Receivables04.85M2.33M5.77M3.17M
Inventory00000
Other Current Assets71K80K102K515K1.79M
Total Current Assets26.07M48.99M53.95M36.61M50.04M
Property, Plant & Equipment (Net)10K6K0252K199K
Goodwill00000
Intangible Assets00000
Long-term Investments00000
Tax Assets00000
Other Non-current Assets00000
Total Non-current Assets10K6K0252K199K
Total Assets26.08M48.99M53.95M36.86M50.24M
Account Payables1.58M1.07M2.15M3.15M3.29M
Short-term Debt538K0000
Tax Payables0315K000
Deferred Revenue00000
Other Current Liabilities0074K2K4.49M
Total Current Liabilities3.86M2.75M4.04M11.3M7.78M
Long-term Debt00000
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities00018.84M27.11M
Total Non-current Liabilities00018.84M27.11M
Total Liabilities3.86M2.75M4.04M30.14M34.9M
Common Stock2K2K2K3K7K
Retained Earnings(89.37M)(71.48M)(81.47M)(139M)(188.59M)
Accumulated OCI00000
Other Stockholders Equity00000
Minority Interest00000
Total Equity22.22M46.24M49.91M6.72M15.35M
Total Debt538K0000
Net Debt(24M)(42.63M)(50.5M)(30.32M)(45.09M)

Opus Genetics, Inc.

NASDAQ:IRD

Intrinsic Alpha fair value

Locked

Current Price

$3.92

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.